What's in Intersect ENT's pipeline?

Intersect ENT has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Intersect ENT's portfolio?

Top competitors by shared drug class: AIDS Malignancy Consortium, ANI Pharmaceuticals, AbbVie, Acrotech Biopharma Inc., Allergan.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/intersect-ent.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Intersect ENT — Portfolio Competitive Intelligence Brief

Intersect ENT pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
S8 Sinus Implant	S8 Sinus Implant	phase 3	Corticosteroid		Otolaryngology

Therapeutic area mix

Otolaryngology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AIDS Malignancy Consortium · 1 shared drug class
ANI Pharmaceuticals · 1 shared drug class
AbbVie · 1 shared drug class
Acrotech Biopharma Inc. · 1 shared drug class
Allergan · 1 shared drug class
Aramis Biosciences, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Intersect ENT:

Cite this brief

Drug Landscape (2026). Intersect ENT — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/intersect-ent. Accessed 2026-05-14.